M Mazzuia Guimarães1, D Dante Cardeal2, M Jacobsen Teixeira2, J Erasmo Dal Col Lucio2, F Hada Sanders2, R Kei Kuromoto2, H Matushita2. 1. Department of Neurosurgery, Hospital das Clínicas, School of Medicine, University of São Paulo, Street Eneas de Carvalho, 155, Pinheiros, São Paulo, Brazil. mazzuiamg@gmail.com. 2. Department of Neurosurgery, Hospital das Clínicas, School of Medicine, University of São Paulo, Street Eneas de Carvalho, 155, Pinheiros, São Paulo, Brazil.
Abstract
PURPOSES: Brachytherapy has been indicated as an alternative option for treating cystic craniopharyngiomas. Despite the difficulties regarding the complex nuclear infrastructure and consequent small number of brachytherapy studies, recent discoveries relating tumour characteristics to sensitivity to brachytherapy have stimulated this extensive systematic review and meta-analysis of the recent results aiming to summarise its efficacy and complications. METHODS: The systematic review was structured using PRISMA statements. The MEDLINE database was systematically reviewed from March 2010 to February 2021 to identify qualified trials dealing with radioisotope brachytherapy in cystic craniopharyngiomas in the paediatric population, emphasising tumour control rates and complications. RESULTS: A total of 228 individuals were analysed, of which 66 were children. The minimum average follow-up was 5 years. Considering the paediatric trials, partial and complete responses were achieved in 89% of patients with exclusively cystic lesions, compared to 58% in non-exclusively cystic lesions. The former observed progression in 3% of patients, while in the latter, 35% was reported. Visual and endocrine improvement reached 64% and 20%, respectively, in the first group, in contrast to 48% and 7% in the second group, respectively. There were similar results considering the non-exclusive paediatric series, but with less expressive numbers. CONCLUSION: These results reinforce the positive impact of radioisotope brachytherapy in the treatment of predominant monocystic or multicystic craniopharyngiomas, especially in the paediatric population, grounded by impressive tumour control rates, lower morbidities and single application in the majority of the cases. In the future, specific morphological tumour characteristics might be considered for a more assertive patient selection.
PURPOSES: Brachytherapy has been indicated as an alternative option for treating cystic craniopharyngiomas. Despite the difficulties regarding the complex nuclear infrastructure and consequent small number of brachytherapy studies, recent discoveries relating tumour characteristics to sensitivity to brachytherapy have stimulated this extensive systematic review and meta-analysis of the recent results aiming to summarise its efficacy and complications. METHODS: The systematic review was structured using PRISMA statements. The MEDLINE database was systematically reviewed from March 2010 to February 2021 to identify qualified trials dealing with radioisotope brachytherapy in cystic craniopharyngiomas in the paediatric population, emphasising tumour control rates and complications. RESULTS: A total of 228 individuals were analysed, of which 66 were children. The minimum average follow-up was 5 years. Considering the paediatric trials, partial and complete responses were achieved in 89% of patients with exclusively cystic lesions, compared to 58% in non-exclusively cystic lesions. The former observed progression in 3% of patients, while in the latter, 35% was reported. Visual and endocrine improvement reached 64% and 20%, respectively, in the first group, in contrast to 48% and 7% in the second group, respectively. There were similar results considering the non-exclusive paediatric series, but with less expressive numbers. CONCLUSION: These results reinforce the positive impact of radioisotope brachytherapy in the treatment of predominant monocystic or multicystic craniopharyngiomas, especially in the paediatric population, grounded by impressive tumour control rates, lower morbidities and single application in the majority of the cases. In the future, specific morphological tumour characteristics might be considered for a more assertive patient selection.
Authors: Anthe S Sterkenburg; Anika Hoffmann; Ursel Gebhardt; Monika Warmuth-Metz; Anna M M Daubenbüchel; Hermann L Müller Journal: Neuro Oncol Date: 2015-04-02 Impact factor: 12.300
Authors: Ana M Denis-Bacelar; Marina Romanchikova; Sarah Chittenden; Frank H Saran; Henry Mandeville; Yong Du; Glenn D Flux Journal: Eur J Nucl Med Mol Imaging Date: 2013-06-06 Impact factor: 9.236
Authors: Giulia Cossu; Emmanuel Jouanneau; Luigi M Cavallo; Samer K Elbabaa; Lorenzo Giammattei; Daniele Starnoni; Juan Barges-Coll; Paolo Cappabianca; Vladimir Benes; Mustafa K Baskaya; Michael Bruneau; Torstein Meling; Karl Schaller; Ari G Chacko; A Samy Youssef; Diego Mazzatenta; Mario Ammirati; Henry Dufour; Edward Laws; Moncef Berhouma; Roy Thomas Daniel; Mahmoud Messerer Journal: Acta Neurochir (Wien) Date: 2020-02-28 Impact factor: 2.216
Authors: Hermann L Müller; Thomas E Merchant; Stephanie Puget; Juan-Pedro Martinez-Barbera Journal: Nat Rev Endocrinol Date: 2017-02-03 Impact factor: 43.330